A Retrospective, Observational Registry of Participants With Avian Influenza Infection

Avian/Pandemic Influenza Registry

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02743676

Enrollment

648

Registered

2016-04-19

Start date

2007-01-31

Completion date

2012-03-31

Last updated

2016-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

Avian Influenza

Brief summary

This is a global, multi-center, observational registry of participants with suspected or confirmed infection with avian influenza A H5N1. Data are collected through retrospective abstraction, from detailed case reports that may be published and available in the public domain, or as incident cases received directly from the treating physician or other medical personnel.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 120 Years

Healthy volunteers

Inclusion criteria

* Participants who develop influenza-like symptoms and who are considered to be epidemiologically linked by time, place, and exposure to a probable or confirmed avian influenza or human case of H5N1 infection are eligible for inclusion in the Registry. Cases with atypical symptom presentation (e.g., non-respiratory) are also included, in keeping with evolving knowledge about the clinical presentation of avian influenza. * Participants with documented positive serological test who either remain asymptomatic or experience mild illness only * Participants with laboratory confirmation of infection with influenza A (H5N1) who survive long enough to present for medical care

Exclusion criteria

\- There are no

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with clinical outcome (death, recovery, or other overall clinical status) at the time of discharge from care	Up to 5 years

Secondary

Measure	Time frame
Number of Participants with at least One Adverse Event (AE)	Up to 5 years

Outcome results